Sana suspends all CAR-T programs, narrows to diabetes and in vivo platform amid litigation

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Company suspended both allogeneic CAR-T programs (SC291 in autoimmune diseases, SC262 in oncology) and is winding down GLEAM and VIVID trials, abandoning a core technology platform to focus exclusively on SC451 diabetes therapy and SG293 in vivo CAR-T.

  MD&A: Portfolio Prioritization verify on EDGAR →
• high

  Securities class action advanced with court-appointed lead plaintiffs and amended complaint filed August 2025, alleging misstatements about SC291 CAR-T candidate. Motion to dismiss and motion to amend both pending.

  Legal Proceedings verify on EDGAR →
• high

  Going concern warning persists despite $25M Mayo Clinic financing closed April 2026 (with $25M option through August). Cash fell to $101M at quarter-end from $105M year-ago, with $47M quarterly burn.

  MD&A: Liquidity verify on EDGAR →